A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

• Status: RECRUITING
• Trial end date: 2031-07-01

Summary

The goal of this study (iMMagine-3) is to compare the study drug, anitocabtagene autoleucel to standard of care therapy (SOCT) in participants with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of therapy, including an anti-CD38 monoclonal antibody and an immunomodulatory drug.

The primary objective of this study is to compare the efficacy of anitocabtagene autoleucel versus SOCT in participants with RRMM.

• Phase: PHASE3

Details

• Lead Sponsor: Kite, A Gilead Company
• Collaborator: Arcellx, Inc.
• Treatments: Bortezomib; carfilzomib; Cyclophosphamide; daratumumab; Dexamethasone; fludarabine; pomalidomide